These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 32348994

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, Hess G, Jurczak W, Knoblauch P, Chawla S, Bhat G, Choi MR, Walewski J, Savage K, Foss F, Allen LF, Shustov A.
    J Clin Oncol; 2015 Aug 10; 33(23):2492-9. PubMed ID: 26101246
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Long-term successful use of belinostat in a patient with relapsed-refractory angioimmunoblastic lymphoma who has previously been heavily treated.
    Atalay F, Yeşilaltay A.
    J Cancer Res Ther; 2024 Apr 01; 20(3):1049-1052. PubMed ID: 39023617
    [Abstract] [Full Text] [Related]

  • 6. Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature.
    Liu Y, Fan L, Zhao H, Xu W, Li J.
    Oncotarget; 2017 May 09; 8(19):32292-32297. PubMed ID: 28427176
    [Abstract] [Full Text] [Related]

  • 7. Belinostat: first global approval.
    Poole RM.
    Drugs; 2014 Sep 09; 74(13):1543-54. PubMed ID: 25134672
    [Abstract] [Full Text] [Related]

  • 8. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience.
    Zhu Y, Gao Q, Hu J, Liu X, Guan D, Zhang F.
    Leuk Res; 2020 Mar 09; 90():106299. PubMed ID: 32035354
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F, Advani R, Duvic M, Hymes KB, Intragumtornchai T, Lekhakula A, Shpilberg O, Lerner A, Belt RJ, Jacobsen ED, Laurent G, Ben-Yehuda D, Beylot-Barry M, Hillen U, Knoblauch P, Bhat G, Chawla S, Allen LF, Pohlman B.
    Br J Haematol; 2015 Mar 09; 168(6):811-9. PubMed ID: 25404094
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH, Foon KA, Frankel P, Ruel C, Pulone B, Tuscano JM, Newman EM.
    Leuk Lymphoma; 2014 Oct 09; 55(10):2301-4. PubMed ID: 24369094
    [Abstract] [Full Text] [Related]

  • 18. How I treat LGL leukemia.
    Lamy T, Loughran TP.
    Blood; 2011 Mar 10; 117(10):2764-74. PubMed ID: 21190991
    [Abstract] [Full Text] [Related]

  • 19. [Hepatocellular failure revealing T-cell large granular lymphocyte leukemia: Morocco case study and literature review].
    Benmoussa A, Oussaih L, Tazi I.
    Pan Afr Med J; 2019 Mar 10; 34():119. PubMed ID: 31934260
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.